Is CVS Health's Pharmacy & Consumer Wellness Poised for a Stronger Q3?

28.10.25 13:33 Uhr

Werte in diesem Artikel
Aktien

71,26 EUR 0,81 EUR 1,15%

Indizes

PKT PKT

18.059,2 PKT -125,2 PKT -0,69%

3.469,8 PKT 23,3 PKT 0,68%

6.890,9 PKT 15,7 PKT 0,23%

The Pharmacy & Consumer Wellness segment at CVS Health CVS is showing strong momentum, driven by the company’s focus on operational excellence and technological upgrades that improve the customer experience. In the first half of 2025, revenues rose 11.8%, fueled by a pharmacy drug mix and higher prescription volume. Despite ongoing pharmacy reimbursement pressure, CVS has demonstrated resilience through consistent execution across its 9,000 local community health destinations, led by more than 200,000 workforce staff. With the third-quarter 2025 results due this week, the segment could emerge as a key contributor to the overall financial performance.   The front store business, which covers over-the-counter drugs, consumer health products, beauty products, personal care products and other general merchandise products, is showing steady improvement from an expanding customer base and continued retail share gains. Further, CVS Pharmacy recently completed the acquisition of select Rite Aid assets nationwide and acquired the prescription files of 626 former Rite Aid and Bartell Drugs pharmacies across 15 states. The company already saw early impact from the scripts in the previous quarter, which are likely to continue in the upcoming report.2025 has also been a transition year for the CVS CostVantage pharmacy reimbursement model, with all of the commercial scripts now shifted and performing in line with the company’s expectations. The model addresses the industry-wide challenge of cross-subsidization across brands and generics, creating more stable and predictable margins while passing the value back to payors in a more transparent manner. That said, CVS continues to maintain a prudent outlook for possible changes in the vaccine market demand and a softening consumer environment. The Zacks Consensus Estimate for CVS’ Pharmacy & Consumer Wellness segment revenues indicates a 7.4% improvement year over year in the third quarter.CVS Health’s Peer UpdatesWalmart WMT is set to report fiscal 2026 third-quarter earnings results on Nov. 20. The company has just announced the highly anticipated Black Friday and Cyber Monday event plans, with the first event starting Nov. 14. Walmart is dropping up to 60% off top brands and offering thousands of deals under $20, differentiating itself in terms of prices. Further, Walmart teamed up with Avery Dennison to advance the use of radio-frequency identification (RFID) technology for fresh categories to improve inventory accuracy and reduce food waste.Amazon AMZN is gearing up to report third-quarter 2025 results on Oct. 30.The company’s cloud computing platform, Amazon Web Services and Accenture recently expanded collaboration to deliver new digital services to public sector, defense and national security organizations. Amazon also launched Amazon Grocery, a new private-label brand featuring more than 1,000 high-quality food items at low, competitive prices.CVS Stock Performance, Valuation and EstimatesIn the past year, CVS Health shares have risen 46.5% against the industry’s 3.1% decline. Image Source: Zacks Investment ResearchCVS Health is trading at a forward five-year price/sales (P/S) of 0.25X, which is discounted from the industry’s 0.48X P/S.Image Source: Zacks Investment ResearchThe Zacks Consensus Estimate for CVS Health’s 2025 EPS has moved up 3.9% in the past 90 days. However, estimates are showing a mixed trend for 2026. Image Source: Zacks Investment ResearchCVS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Walmart Inc. (WMT): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: CVS Health und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf CVS Health

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf CVS Health

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu CVS Health Corp

Wer­bung

Analysen zu CVS Health Corp

DatumRatingAnalyst
05.06.2019CVS Health BuyStandpoint Research
15.04.2019CVS Health PerformOppenheimer & Co. Inc.
12.04.2019CVS Health Market PerformBMO Capital Markets
18.12.2018CVS Health OverweightBarclays Capital
26.10.2018CVS Health Peer PerformWolfe Research
DatumRatingAnalyst
05.06.2019CVS Health BuyStandpoint Research
12.04.2019CVS Health Market PerformBMO Capital Markets
18.12.2018CVS Health OverweightBarclays Capital
30.01.2018CVS Health Strong BuyNeedham & Company, LLC
02.01.2018CVS Health BuyNeedham & Company, LLC
DatumRatingAnalyst
15.04.2019CVS Health PerformOppenheimer & Co. Inc.
26.10.2018CVS Health Peer PerformWolfe Research
28.06.2017CVS Health HoldNeedham & Company, LLC
02.02.2017CVS Health NeutralRobert W. Baird & Co. Incorporated
22.06.2016CVS Health HoldDeutsche Bank AG
DatumRatingAnalyst
25.07.2005Update Longs Drug Stores Corp.: UnderperformBear Stearns

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für CVS Health Corp nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen